A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T‐CELL LYMPHOMA (PTCL). (June 2017) - Amengual, J.E.; Lichtenstein, R.; Lue, J.K.; Sawas, A.; Deng, C.; Lichtenstein, E.; Khan, K.; Kim, H.; Atkins, L.; Turenne, I.; Rojas, C.; Chiuzan, C.; et al.